| Identification | Back Directory | [Name]
1,7,9-Triazaspiro[4.5]dec-1-ene-6,10-dione, 2,4-bis(4-chlorophenyl)-8-thioxo- | [CAS]
2377858-38-1 | [Synonyms]
SCR130
1,7,9-Triazaspiro[4.5]dec-1-ene-6,10-dione, 2,4-bis(4-chlorophenyl)-8-thioxo-
DNA/RNA Synthesis,NHEJ,Inhibitor,SCR130,Apoptosis,Ligase-IV,DNA,anticancer,p-p53,SCR 130,cytotoxicity,inhibit,SCR-130 | [Molecular Formula]
C19 H13 Cl2 N3 O2 S | [MDL Number]
MFCD34474410 | [MOL File]
2377858-38-1.mol | [Molecular Weight]
418.3 |
| Chemical Properties | Back Directory | [density ]
1.57±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
sonicated),: DMSO | [form ]
Solid | [pka]
7.30±0.60(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
SCR130 is a SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor. SCR130 inhibits the end-joining of DNA in a Ligase IV-dependent manner. SCR130 is specific to Ligase IV, and shows minimal or no effect on Ligase III and Ligase I mediated joining. SCR130 induces cell apoptosis and has anticancer activity[1]. | [References]
[1] Ujjayinee Ray, et al. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics. Mol Carcinog. 2020 Jun;59(6):618-628. DOI:10.1002/mc.23186 |
|
|